Agenus (AGEN) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on immunotherapies for cancer and infectious disease, with a primary emphasis on immuno-oncology antibody-based programs.

• Lead clinical program is botensilimab (BOT), alone and in combination with balstilimab (BAL), targeting activation of innate and adaptive immunity and overcoming tumor immune evasion.

• Holds equity in MiNK Therapeutics and majority ownership of vaccine adjuvant business SaponiQx; leverages internal R&D and strategic collaborations.

• Strategic realignment in December 2024 prioritized the BOT/BAL program and paused certain non-core activities pending partnerships or targeted funding.

Financial performance and metrics

• Research and development expenses were $79.3M (2025), $155.5M (2024), and $234.6M (2023).

• Accumulated deficit of $2.14B as of March 31 and June 30, 2026; significant losses since inception and not yet profitable.

• Audit report notes recurring losses and net capital deficiency raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Entitled to receive cash proceeds only from the exercise of New Warrants; no proceeds from sale of shares by selling stockholders.

• Proceeds from warrant exercises are not guaranteed as selling stockholders are not obligated to exercise.

• Company bears all registration costs; selling stockholders pay brokerage commissions.